How effective is CAR T-cell therapy for leukaemia patients in India?

Leukaemia is a blood disease that arises from the bone marrow and produces white blood cells. Many patients recover from chemotherapy, targeted therapy, or stem cell transplantation, while others either have repeated disease or cannot be cured, thus having a return of cancer despite standard treatment. In this case, Chimeric Antigen Receptor (CAR) T-cell therapy has become a potential breakthrough in cancer therapy.

India has efficiently adopted this new treatment option, which now follows a more wide-ranging pattern in terms of accessibility and cost than in other countries. Organisations in India are developing their own CAR T-cell products and specialised centres to provide similar therapies at home.

The current post will discuss various aspects of CAR T-cell therapy, including its various characteristics, its effectiveness in treating a patient suffering from leukaemia in India, the eligibility criteria for undergoing the treatment, the costs involved, and the health complications one may have.

What is CAR T-cell therapy?

CAR T-cell therapy is a type of immunotherapy where the immune cells of the patient are utilised to combat the disease instead of using chemotherapy or radiotherapy.

The therapy consists of a systematic process which includes the following stages:

The extraction of T-cells from the patient's blood. The extraction process is known as leukapheresis.
After extraction, the T-cells are taken to a laboratory, where they undergo genetic modification to express CARs.
After the modification, the modified cells are multiplied into billions of CAR T-cells.
The patient is then subjected to a short chemotherapy regimen before being infused with CAR T cells.
The CAR T-cells injected into the patient's body have a unique property of being able to attack leukaemia cells that express specific marker molecules on them.

One distinction of CAR T-cell therapy compared with chemotherapy is that it can continue working in the patient's body long after the infusion.

Which Leukaemia Patients Can Benefit?

At present, CAR T-cell therapy is used for several types of leukaemia as well as sometimes for patients with Advanced B-cell Acute Lymphoblastic Leukaemia (B-ALL).

The approved methods are being tested to treat Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL) and other forms of leukemia as well as other types of blood disorders.

Patients are carefully examined by professional haematologists and bone marrow transplant specialists.

Higher-quality sampling of caregivers gives them the know-how and makes them feel good when interacting with patients.

How Effective Is CAR T-Cell Therapy?

CAR T-cell therapy has changed the lives of several patients who were left with few options after not responding adequately to other treatment methods.

Clinical studies have revealed the following:

Complete remission rates of 70-90% among patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
Some patients become MRD negative
An important improvement in the survival rate among patients with a poor prognosis before treatment
Decreased usage of chemotherapy in many patients who respond positively

Nevertheless, the results vary from patient to patient. The effectiveness depends on a wide range of variables, including the type of leukaemia, the stage of the disease, previous treatments, and overall health.

CAR T-Cell therapy in India

India offers CAR T-cell therapy, one of the most important options for the treatment of leukaemia. Some hospitals have already begun offering CAR T-cell therapy in line with international protocols, while others have developed and used their own methods.

Patients in India can get access to CAR T-cell therapy, which is duly approved by local authorities. The domestic production of CAR T-cells has enabled the final price of such therapy to be reduced while maintaining high quality.

CAR T-Cell Therapy Advantages

The benefits resulting from CAR T-cell therapy innovation based on a unique method of utilising the patientâ€™s own immune cells include the following:

Patient's cells are used in the treatment process
Highly specific and efficient in fighting leukaemia
Allows use of CAR T-cell therapy for patients relapsing after prior chemotherapy
Causes a long and durable response in eligible patients
May provide less dependence on chemotherapy

CAR T-cell therapy can provide hope for many families after exhausting all standard therapies.

Disadvantages of CAR T-Cell Therapy

Despite being highly efficient, CAR T-cell therapy has several disadvantages that should be mitigated by high-quality professional care.

Cytokine Release Syndrome (CRS)

The majority of problems occur during treatment. Cytokine Release Syndrome is characterised by the reaction to usage of activated T-cells. In this case, T-cells produce large amounts of cytokines, which are also called inflammatory proteins.

Neurological Problems

Some patients may develop problems related to their immunotherapy. One may be confused about their health, have headaches, and experience speech difficulties.

Decreased Blood Count

The condition may appear due to the chemotherapy before the CAR T-cell therapy procedure.

How Much is CAR T-Cell Therapy in India?

According to a study, "India's homegrown NexCAR19 has made CAR T-cell therapy significantly more accessible, reducing treatment costs to around USD 50,000, nearly one-tenth of the USD 380,000-526,000 cost in the U.S. Early clinical trials reported an 87.5% overall response rate, supporting its potential as an effective and more affordable treatment for blood cancers."

The cost of CAR T-cell therapy in India is much lower than in other countries. For instance, the cost for CAR T-cell therapy in the United Kingdom is approximately USD 373,00 and 475,000, while CAR T-cell therapy in India will be in the range of USD 45,000 and USD 65,000 depending on:

The type of CAR T product
The place where treatment is done
The degree of intensive care needed
Time spent in the hospital
Other supportive medicines needed
Tests and examinations required

Patients are urged to consider accommodation, follow-up visits, and the costs of supportive care when making their decision.

Recovering after CAR T-Cell Treatment

The recovery time varies from one patient to another. Most patients spend about two to three weeks in the hospital so doctors can monitor for complications. The patients will receive regular check-ups, and blood samples will be taken for assessment.

Is CAR T-Cell Therapy More Effective than Bone Marrow Transplantation?

CAR T-cell therapy and bone marrow transplantation are crucial treatment modalities for leukaemia, with different functionalities.

Bone marrow transplantation involves transplanting healthy stem cells to cure the patient by replacing the diseased bone marrow and has been used for many years. On the other hand, CAR T-cell therapy utilises one's own immunity to treat the patient.

In some cases, CAR T-cell therapy can replace the transplantation process entirely for patients, while some patients can get CAR T-cell therapy and later undergo a stem cell transplant after they achieve a remission state. The choice between the two treatment methods depends on the patient's specific condition and other factors, including health status.

The Future of CAR T-Cell Therapy in India

Currently, India is developing next-generation CAR T-cells to improve the quality of the therapy and reduce unwanted effects. The country is also using CAR T-Cell Therapy for treating other blood cancers apart from leukaemia.

As biotechnology investments increase rapidly, CAR T-cell therapy is expected to gain popularity and acceptance in the near future.

Conclusion

CAR T-Cell therapy has changed the way leukaemia is treated. The fact that genetically modified immune cells can target cancer is another reason the treatment is highly effective at achieving remission. The therapy not only provides a chance to recover even when the patientâ€™s situation becomes critical, but it is also proving to be very efficient and effective.

Moreover, it is worth mentioning that CAR T-Cell therapy cannot be used by all people, and consultation with a doctor is highly recommended before any decision-making regarding the use of CAR T-Cell Therapy because the therapy is not a universal treatment for all patients with leukaemia. Doctors can consider the patient's medical history and personal situation in relation to the therapy and only then decide on the feasibility of CAR T-Cell Therapy for the patient.

Frequently Asked Questions

CAR T-cell therapy is advised mainly for patients with relapsed or refractory B-cell leukaemia that did not respond to standard treatment options like chemotherapy or stem cell transplant. Eligibility is confirmed after a careful examination by a hematologist.

Clinical research indicates that complete remission rates usually fall somewhere in between 70% and 90% among eligible patients suffering from relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL). There is variation in outcomes among patients according to their clinical status and other disease features.

The cost of CAR T-cell therapy in India typically ranges from USD 45,000 to USD 65,000, depending on the hospital, CAR T-cell product used, hospitalisation, and supportive care. This is considerably lower than the cost in many Western countries.

CAR T-cell therapy and bone marrow transplant have different roles. CAR T-cell therapy, which uses the patient's own immune cells, can find and kill cancer cells. On the contrary, a bone marrow transplant involves replacing diseased bone marrow with the donor's healthy stem cells. The necessity of treatment will be determined by the type of disease, the history of the treatments received, and the matches between the patient and the donor.

Usually, patients stay in the hospital for 2 to 3 weeks after receiving treatment because they need constant monitoring and their health condition should be monitored.